Prelude Capital Management’s TherapeuticsMD TXMD Stock Holding History

Prelude Capital Management’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-220	Closed	-$4K	–	2246
2021 Q4	$4K	Buy	+220	New	+$6.59K	﹤0.01%	1957
2021 Q2	–	Sell	-206	Closed	-$14K	–	1972
2021 Q1	$14K	Buy	+206	New	+$16.1K	﹤0.01%	1482
2020 Q4	–	Sell	-14	Closed	-$1K	–	2010
2020 Q3	$1K	Hold	14	–	–	﹤0.01%	1736
2020 Q2	$1K	Buy	+14	New	+$815	﹤0.01%	1891

Other funds holding TXMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Prelude Capital Management's TXMD Position: Q1 2020 in Review

Prelude Capital Management sold out of TherapeuticsMD (TXMD) in Q1 2020, closing a stake of 28 shares — an estimated $3K sold.

Prelude Capital Management first reported a position in TXMD in Q4 2013 and held it in 6 quarters. The position peaked at $365K in Q4 2013. 143 funds tracked by Wall St. Rank hold TXMD as of Q1 2020.

Prelude Capital Management reported no remaining TherapeuticsMD position as of Q1 2020 after selling out during the quarter.
Prelude Capital Management sold 28 TherapeuticsMD shares in Q1 2020, an estimated $3K.
Prelude Capital Management first reported a position in TherapeuticsMD in Q4 2013 and held it in 6 quarters.
Prelude Capital Management's TherapeuticsMD position peaked at $365K in Q4 2013.
143 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2020.

Based on Prelude Capital Management's 13F filing for Q1 2020, filed 15 May 2020.